Detection Of Biomarkers For Non-Small Cell Lung Cancer
AssigneesSengenics Sdn Bhd, National University of Singapore
InventorsJonathan Michael BLACKBURN, Arif ANWAR, Boon Cher GOH, Lingzhi WANG, Sok Hwee Esther CHEOW, Ross Andrew SOO, Win Lwin THUYA
Life of this patent
Estimating the term…
Abstract
A method for diagnosing Non-Small Cell Lung Cancer (NSCLC) from a sample extracted from a subject by testing the sample for the presence of biomarkers, the biomarkers being autoantibodies against XAGE1D, LRRFIP2, and GAGE2C. Also claimed are a method of manufacturing a kit, and compositions comprising a panel of said antigens or exosomal autoantibodies.
Claims14
1-19. (canceled)
A method for diagnosing Non-Small Cell Lung Cancer from a sample comprising serum and/or plasma extracted from a subject, comprising the steps of:
- (i) testing the sample for the presence of biomarkers specific for Non-Small Cell Lung Cancer;
- (ii) determining whether the subject has Non-Small Cell Lung Cancer based on the detection of said biomarkers;
- characterised in that the biomarkers are autoantibodies to antigens comprising XAGE1D, LRRFIP2 and GAGE2C.
A method for manufacturing a kit for diagnosing Non-Small Cell Lung Cancer from a sample extracted from a subject, comprising the steps of:
- for each antigen in a panel, cloning a biotin carboxyl carrier protein folding marker in-frame with a gene encoding the antigen and expressing the resulting biotinylated antigen;
- binding the biotinylated proteins to addressable locations on one or more streptavidin-coated substrates, thereby forming an antigen array;
- such that the amount of autoantibodies from the sample binding to the antigens on the panel can be determined by exposing the substrate to the sample and measuring the response;
- characterised in that the antigens comprise XAGE1D, LRRFIP2 and GAGE2C.
Dependencies are inferred from the claim text.